SOMAí Pharmaceuticals January 2024 Newsletter
January
As we enter the new year, SOMAí Pharmaceuticals is all set for a new chapter in the global medicinal cannabis industry. Get ready for the biggest product launch with key partnerships worldwide. Our innovative products are all set to hit the shelves in Australia, Germany, the UK, and Poland, marking a historic leap in our global influence. Our mission is to advance pharmaceutical research, delivering ground-breaking product lines every month. Stepping into new frontiers, we're not just leaving a mark but forming strong bonds with like-minded partners. Expect a year of innovation and dedication as SOMAí Pharmaceuticals leads the way in shaping the global future of medicinal cannabis to a brighter and bolder future for healthcare and patients' well-being.
We're introducing the broadest medicinal cannabis portfolio, with different product lines, including Oral Solutions and Spray lines, Soft Gel Capsules, Inhalation Oil cartridges, Proprietary Formulations, and Transdermal Patches and Creams to meet the evolving patients' needs. As of January, we are finalizing the preparations for the highly anticipated release of our inaugural product line – SOMAí Oral Solutions, set to hit the markets in February.
Following the recent INFARMED inspection, we're progressing well in enhancing our EU-GMP certification and broadening our production capabilities. We remain focused on our commitment to innovation and quality, aiming to meet and exceed the European Monograph's standards. As we await the final report, we are confident in our course and look forward to further advancements in our operations. At SOMAí, we believe investing in R&D is essential for transformative change and to help more patients worldwide. In January, our Research and Development program achieved remarkable results with the development of new formulations, which are sure to revolutionize the medicinal cannabis industry.
January was also a month full of news and events. SOMAí Pharmaceuticals has entered into a non-binding letter of intent (LOI) with Akanda Corporation, a global medical cannabis company listed on Nasdaq (AKAN). The LOI outlines the acquisition of Akanda's subsidiary, RPK Biopharma, based in Sintra, Portugal. The deal, extended until March 31, 2024, involves SOMAí paying $2 million (€1.84 million) and assuming around $4 million in debt from RPK Biopharma. This includes acquiring real estate and cannabis cultivation licenses in Sintra and Aljustrel.
SOMAí Pharmaceuticals announced its partnership with Airo Brands Inc. The partnership enables SOMAí to exclusively manufacture and distribute Airo's award-winning products to the Australian, German, Polish, and Swiss medical markets alongside SOMAí's manufactured inhalation oils, adhering to the highest standards to ensure product safety and quality. The anticipated SOMAí and Airo collaborative products are expected to be available for distribution starting in Q2 2024.
Continuing the momentum, SOMAí participated in Cannabis Invest UK, where our Founder and CEO, Michael Sassano, spoke about the latest advancements in cannabis biotechnology, exploring the opportunities and challenges in conducting research in this dynamic industry during the "The Impact of Clinical Trials, APIs and Extracts on Medical Cannabis" panel. "Cannabis Invest UK was one of the most exclusive events, with some of the most important cannabis people speaking, like William Muecke and Tristan Jervais. I was proud to be one of 12 speakers at this event, and the consensus was that if US rescheduling and German rescheduling occurs, the global cannabis markets are going to explode,” shares Michael Sassano.
SOMAí Pharmaceuticals has launched a brand-new website. Explore comprehensive information about our company, values, team, capabilities, and our extensive range of medicinal cannabis products. Access valuable educational resources designed for both patients and healthcare professionals. Stay informed with our latest news, updates, job opportunities, and much more.
领英推荐
February 2024
SOMAí Oral Solutions will be officially launched in February 2024 in Australia, Germany, the UK, and Poland. Our formulations are crafted with precision, purity, and taste and represent our commitment to providing patients with tailored medicinal cannabis options. At SOMAí Pharmaceuticals, our primary goal is to revolutionize global medicinal cannabis markets by delivering exceptional products that cater to the diverse needs of patients.
Learn more about our products in the Product Catalogue
We're constantly improving our terpene extraction methods and equipment to ensure top quality and efficiency — this ongoing commitment to improvement positions us to offer new, next-gen products later this year. Our robust and better-tasting product portfolio is set to evolve with proprietary terpene taste profiles, promising to revolutionize existing product lines.
SOMAí Pharmaceuticals is excited to participate in the Cannabis Business Asia-Pacific 2024 event, scheduled for 29 February - 1st of March in Bangkok, Thailand. Michael Sassano, our CEO, and Founder, will share insights into the company's vision of creating products of the future considering the Golden Standards of the medicinal cannabis industry.
During the whole of February, Michael Sassano will also embark on a business tour across Australia and Asia. His trip schedule:?
If you're interested in exploring potential collaborations with SOMAí Pharmaceuticals, don't hesitate to schedule a meeting by reaching out to [email protected].
Get ready for the launch of our latest, more advanced product lines every month – stay tuned for the excitement! We're crafting products for today, tomorrow, and beyond.
Latest articles from our CEO, Michael Sassano